Therefore, manipulating specific downstream targets of HIF-2α provides a new to be further evaluated perspective for restoring reduced neovascularization in several pathological conditions, such as diabetic, ulcers or other chronic wounds, or for improvement of vascularization of implanted tissue-engineered scaffolds. This evidence concerns the gene EPAS1 and ulcer disease.